Generic name · Weight Loss
Liraglutide(lir a gloo' tide)
Liraglutide is the active ingredient in Saxenda. FDA-approved in 2014.
FDA Boxed Warning (liraglutide class-effect)
Risk of thyroid C-cell tumors. Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Brand names of liraglutide
Currently only one brand markets liraglutide in the US.
Saxenda
Novo Nordisk · FDA-approved 2014
FDA-approved daily injectable liraglutide for chronic weight management. Older-generation GLP-1, daily dosing.
Primary sources
Aggregated from the FDA prescribing information и pivotal trials for every brand of liraglutide.